Noxopharm Clears Key Safety Milestone as HERACLES Trial Concludes and Sofra Platform Gains Global Traction

The latest announcement is out from Noxopharm Ltd. ( (AU:NOX) ).

Noxopharm reported a strong December quarter, highlighted by the successful completion of dosing in all cohorts of its milestone HERACLES clinical trial evaluating SOF-SKN™, which delivered highly positive safety and tolerability results and clears a key regulatory hurdle ahead of planned Phase II-enabling studies. The company also broadened the potential applications of its Sofra platform through a new Material Transfer Agreement with an overseas partner developing an innovative drug-delivery system for inflammatory bowel disease, secured its first US “first-tier” composition of matter patent protecting its immune-modulatory oligonucleotides for cancer treatment, and received high-profile recognition from the Victorian Government and the scientific community, reinforcing its positioning at the cutting edge of RNA technology and bolstering the platform’s credibility with investors and collaborators.

The most recent analyst rating on (AU:NOX) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Noxopharm Ltd. stock, see the AU:NOX Stock Forecast page.

More about Noxopharm Ltd.

Noxopharm Limited is an Australian clinical-stage drug development company focused on RNA and oligonucleotide-based therapeutics through its Sofra™ technology platform. The company is advancing immune-modulatory oligonucleotides aimed at treating autoimmune diseases such as lupus and inflammatory bowel disease, as well as certain cancers, and collaborates with research partners including Melbourne’s Hudson Institute of Medical Research to translate early-stage discoveries into clinical applications.

Average Trading Volume: 93,736

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$23.38M

For a thorough assessment of NOX stock, go to TipRanks’ Stock Analysis page.